Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2025)
Talphera's (TLPH) quarterly Net Income towards Common Stockholders came in at $73000.0 in Q1 2025, up 101.62% quarter-over-quarter from -$4.5 million in Q4 2023.
Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Talphera's Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $73000.0 for Q1 2025.
- On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to $73000.0 in Q1 2025; TTM through Dec 2025 was $73000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $73000.0, changed N/A from the prior year.
- Net Income towards Common Stockholders rose to $73000.0 in Q1 2025 per TLPH's latest filing, from -$4.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $63.2 million in Q2 2022 and bottomed at -$9.9 million in Q2 2021.
- The 4-year median for Net Income towards Common Stockholders is -$4.5 million (2023), against an average of $698076.9.
- Across the five-year window, Net Income towards Common Stockholders surged 741.07% in 2022 and slumped 106.92% in 2023, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$7.9 million in 2021, then soared by 34.37% to -$5.2 million in 2022, then gained by 13.3% to -$4.5 million in 2023, then jumped by 101.62% to $73000.0 in 2025.
- Per Business Quant, the three latest TLPH Net Income towards Common Stockholders figures stand at $73000.0 (Q1 2025), -$4.5 million (Q4 2023), and -$1.4 million (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.51 Bn | 30.57 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Talphera | 91.82 Mn | 91.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2023 | -4.51 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.37 Mn |
| Mar 31, 2023 | 8.22 Mn |
| Dec 31, 2022 | -5.20 Mn |
| Sep 30, 2022 | -6.94 Mn |
| Jun 30, 2022 | 63.15 Mn |
| Mar 31, 2022 | -4.06 Mn |
| Dec 31, 2021 | -7.92 Mn |
| Sep 30, 2021 | -8.38 Mn |
| Jun 30, 2021 | -9.85 Mn |
| Mar 31, 2021 | -9.74 Mn |
| Dec 31, 2020 | -8.92 Mn |
| Sep 30, 2020 | -8.93 Mn |
| Jun 30, 2020 | -6.61 Mn |
| Mar 31, 2020 | -16.77 Mn |
| Dec 31, 2019 | -14.42 Mn |
| Sep 30, 2019 | -12.73 Mn |
| Jun 30, 2019 | -12.41 Mn |